Page 1

Better Health , Brighter Future Takeda Takeda Information Revision of the Summary of Financial Statements for the Three - month Period Ended June 30 , 2021 ( IFRS , Consolidated ) OSAKA , Japan , August 6 , 2021 – Takeda Pharmaceutical Company Limited ( TSE : 4502 / NYSE : TAK ) ( “ Takeda " ) today revised the “ Summary of Financial Statements for the Three - month Period Ended June 30 , 2021 ( IFRS , Consolidated ) " disclosed on July 30 , 2021 , which reflected the impact of the subsequent event . Takeda also resubmitted the revised XBRL information . 1. Details of the Subsequent Event Takeda received a decision by the Irish Tax Appeals Commission on July 30 , 2021 ( IST ) to uphold the Irish Revenue Commissioners ' position related to the treatment of a break fee received by Shire plc ( " Shire " ) in October 2014 from AbbVie Inc. ( " AbbVie ” ) . For the details , please refer to the press release , “ Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie ” , announced on August 2 , 2021 . The decision was a subsequent event that related to a condition that existed as of June 30 , 2021. Accordingly , Takeda revised the consolidated financial results for the fiscal quarter , which ended on June 30 , 2021 ( " Q1 FY2021 " ) . 2. Revision Takeda recorded a tax charge of 62.7 billion JPY , including interest accrued through June 30 , 2021 , net of 0.5 billion JPY associated tax benefits , to its Q1 FY2021 consolidated financial statements . This tax charge arose from the case is a non - recurring item unrelated to Takeda's ongoing operations , therefore , there is no change to Takeda's Q1 FY2021 Core and Underlying financial results . Please refer to the underlined items of the attached document where revisions were made .